PLX51107 and PLX2853 BETi upregulate BIM in DHL/DEL DLBCL cell lines. (A) SUDHL6, OCI-LY1, OCI-LY8, and DOHH2 were treated with 1000 nM PLX5, 100 nM PLX2, or a DMSO vehicle control (Con) for 48 hours, and viability was assessed by annexin V/PI staining. Points depict the averages of 3 to 6 independent experiments per cell line, each performed in triplicate. (B-C) DOHH2 or SUDHL6 were treated as in panel A, and BIM protein expression was assessed (i). Lysates were subjected to BCL-2 immunoprecipitation and assessed for BIM coimmunoprecipitation (ii). (D) SUDHL6, DOHH2, and OCI-LY8 were treated with 1000 nM PLX5, 100 nM PLX2, or DMSO vehicle control (Con) for 24 hours, and miR-17-5p and -92a expression was assessed by qPCR in triplicate. U6 snRNA was used as an internal control. Error bars represent SEM. Statistical analyses were performed by 2-way ANOVA, and P values were adjusted using Dunnett’s multiple comparisons tests. ****P < .00005, ***P < .0005, **P < .005, *P < .05.